Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 700 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR... May 28, 2021 Workout Wednesdays – Leg Exercises Part 3 June 24, 2020 Should People Over Age 75 Be Screened for Colorectal Cancer? June 15, 2021 Phytochemicals and Antioxidants December 11, 2020 Load more HOT NEWS What the Reignited Cancer Moonshot Initiative Means for People With Cancer How do we die of cancer? What we know (and what... Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib... How to Tell If Cancer Information on Social Media Is “Fake...
